Table 1 Clinical and pathological characteristics of the study population

Age at diagnosis (years, IQR) ^a

55.50 (49.00-66.75)

51.50 (50.00-68.25)

56.50 (45.00-66.75)

0.764^c

Age at diagnosis, n (%) ^b

1.000^d

 ≤ 50years

14 (38.9)

4 (28.6)

10 (71.4)

 > 50years

22 (61.1)

6 (27.3)

16 (72.7)

FIGO stage (2018), n (%) ^b

1.000^d

 IA-IIA

2 (5.6)

0 (0.0)

2 (100.0)

 IIB-IVB

34 (94.4)

10 (29.4)

24 (70.6)

Histological type, n (%) ^b

0.370^d

 Squamous cell carcinoma

29 (80.6)

7 (24.1)

22 (75.9)

 Adenocarcinoma

7 (19.4)

3 (42.9)

4 (57.1)

Histological differentiation, n (%) ^b

0.608^d

 G1 well-differentiated

3 (8.3)

1 (33.3)

2 (66.7)

 G2 moderately-differentiated

15 (41.7)

6 (40.0)

9 (60.0)

 G3 poorly- differentiated

3 (8.3)

0 (0.0)

3 (100.0)

 Unknown

15 (41.7)

3 (20.0)

12 (80.0)

Maximal tumor size (cm, IQR) ^a

5.35 (4.03–6.98)

5.55 (4.63–7.48)

5.30 (3.98–6.90)

0.243^c

Maximal tumor size (cm), n (%) ^b

0.155^d

 ≤ 4

7 (19.4)

0 (0.0)

7 (100.0)

 > 4

29 (80.6)

10 (34.5)

19 (65.5)

Lymph nodes metastases, n (%) ^b

0.463^d

 Yes

17 (47.2)

6 (35.3)

11 (64.7)

 No

19 (52.8)

4 (21.1)

15 (78.9)

HPV status, n (%) ^b

0.597^d

 Positive

18 (50.0)

4 (22.2)

14 (77.8)

 Negative

2 (5.6)

1 (50.0)

1 (50.0)

 Unknown

16 (44.4)

5 (31.3)

11 (68.7)

BMI ^b

0.549^d

 ≤ 18.5

2 (5.6)

0 (0.0)

2 (100.0)

 18.5 < BMI ≤ 25

20 (55.6)

5 (25.0)

15 (75.0)

 25 < BMI ≤ 30

12 (33.3)

5 (41.7)

7 (58.3)

 > 30

2 (5.6)

0 (0.0)

2 (100.0)

Menstrual status ^b

0.438^d

 Pre- menopausal status

12 (33.3)

2 (16.7)

10 (83.3)

 Post-menopausal status

24 (66.7)

8 (33.3)

16 (66.7)

Hypertension history ^b

1.000^d

 No

25 (69.4)

7 (28.0)

18 (72.0)

 Yes

11 (30.6)

3 (27.3)

8 (72.7)

Diabetes history ^b

0.181^d

 No

33 (91.7)

8 (24.2)

25 (75.8)

 Yes

3 (8.3)

2 (66.7)

1 (33.3)

Marital status ^b

0.545^d

 Married

33 (91.7)

10 (30.3)

23 (69.7)

 Divorced

3 (8.3)

0 (0.0)

3 (100.0)

Socioeconomic status ^b

0.708^d

 Lower

9 (25.0)

2 (22.2)

7 (77.8)

 Middle

17 (47.2)

6 (35.3)

11 (64.7)

 Upper

10 (27.8)

2 (20.0)

8 (80.0)

EBRT treatment modality ^b

0.686^d

 With CCT

27(75.0)

7(25.9)

20(74.1)

 Without CCT

9(25.0)

3(33.3)

6(66.7)